Anas Mansour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anas Mansour has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Aya Samy
Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 shared publications - Kholoud Elsamman
Ain Shams University
2 shared publications - Nourhan Hatem
Faculty of Medicine, Suez Canal University, Suez, Egypt
2 shared publications - Salma Allam
Faculty of Medicine, Galala University, Suez, Egypt
2 shared publications - Yehia Nabil
Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 shared publications - Abdallah Abbas
Faculty of Medicine Al‐Azhar University Damietta Egypt
1 shared publication
Latest Publications
- Open Access
- 4 July 2026
- Published by Springer Nature in BMC Sports Science, Medicine and Rehabilitation
- Vol. 18 (1)
Comparative effects of pilates-based interventions on functional mobility, balance, fatigue, and quality of life in people with multiple sclerosis: a systematic review and network meta-analysis
Purpose: Pilates-based exercise has gained attention as a non-pharmacological rehabilitation strategy for people with multiple sclerosis (MS), yet the comparative effectiveness of different Pilates modalities remains uncertain. This systematic review and network meta-analysis evaluated and ranked Pilates-based interventions for functional mobility, balance, walking performance, fatigue, and health-related quality of life in adults with MS. Methods: PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched from inception to October 24, 2025. Eligible studies were randomized controlled trials of structured Pilates-based interventions lasting at least four weeks in adults with MS. The primary outcome was functional mobility measured by the Timed Up and Go test. Secondary outcomes included balance, walking endurance, fatigue, walking performance, and MS-specific quality of life. A frequentist random-effects network meta-analysis was performed; treatment ranking was summarized using SUCRA, risk of bias using RoB 2, and certainty of evidence using GRADE-NMA through CINeMA. Results: Twenty-two randomized controlled trials involving 901 participants were included. Pilates ranked first for functional mobility and significantly improved Timed Up and Go performance versus control (MD: -5.23 s; 95% CI: -6.39 to -4.06). It also ranked first for balance, with a mean improvement of 8.58 points on the Berg Balance Scale (95% CI: 7.86 to 9.30). Pilates combined with Pilates-based telerehabilitation ranked highest for the 6-Minute Walk Test (MD: 50.81 m; 95% CI: 0.16 to 101.46) and significantly improved Fatigue Severity Scale scores. Home-based Pilates showed the largest reduction in Modified Fatigue Impact Scale scores. No comparison reached high certainty under GRADE-NMA. Conclusion: Pilates-based interventions may improve mobility, balance, walking endurance, fatigue, and quality of life in people with MS. Sparse networks, risk of bias, heterogeneity, imprecision, and limited follow-up warrant cautious interpretation. Adequately powered trials with standardized protocols are needed before routine implementation can be recommended.
- 4 July 2026
- Published by Springer Nature in BMC Sports Science, Medicine and Rehabilitation
- Vol. 18 (1)
Open AccessComparative effects of pilates-based interventions on functional mobility, balance, fatigue, and quality of life in people with multiple sclerosis: a systematic review and network meta-analysis
Purpose: Pilates-based exercise has gained attention as a non-pharmacological rehabilitation strategy for people with multiple sclerosis (MS), yet the comparative effectiveness of different Pilates modalities remains uncertain. This systematic review and network meta-analysis evaluated and ranked Pilates-based interventions for functional mobility, balance, walking performance, fatigue, and health-related quality of life in adults with MS. Methods: PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched from inception to October 24, 2025. Eligible studies were randomized controlled trials of structured Pilates-based interventions lasting at least four weeks in adults with MS. The primary outcome was functional mobility measured by the Timed Up and Go test. Secondary outcomes included balance, walking endurance, fatigue, walking performance, and MS-specific quality of life. A frequentist random-effects network meta-analysis was performed; treatment ranking was summarized using SUCRA, risk of bias using RoB 2, and certainty of evidence using GRADE-NMA through CINeMA. Results: Twenty-two randomized controlled trials involving 901 participants were included. Pilates ranked first for functional mobility and significantly improved Timed Up and Go performance versus control (MD: -5.23 s; 95% CI: -6.39 to -4.06). It also ranked first for balance, with a mean improvement of 8.58 points on the Berg Balance Scale (95% CI: 7.86 to 9.30). Pilates combined with Pilates-based telerehabilitation ranked highest for the 6-Minute Walk Test (MD: 50.81 m; 95% CI: 0.16 to 101.46) and significantly improved Fatigue Severity Scale scores. Home-based Pilates showed the largest reduction in Modified Fatigue Impact Scale scores. No comparison reached high certainty under GRADE-NMA. Conclusion: Pilates-based interventions may improve mobility, balance, walking endurance, fatigue, and quality of life in people with MS. Sparse networks, risk of bias, heterogeneity, imprecision, and limited follow-up warrant cautious interpretation. Adequately powered trials with standardized protocols are needed before routine implementation can be recommended.
- Open Access
- 19 May 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1) , 326
The impact of caffeine consumption on migraine: a systematic review
Migraine is a common, disabling neurological disorder affecting over one billion people worldwide, characterized by recurrent unilateral, pulsating headach
- 19 May 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1) , 326
Open AccessThe impact of caffeine consumption on migraine: a systematic review
Migraine is a common, disabling neurological disorder affecting over one billion people worldwide, characterized by recurrent unilateral, pulsating headach
- Open Access
- 19 February 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Transcranial alternating current stimulation for chronic insomnia: a meta-analytic evaluation of sleep restoration and safety in adults
Chronic insomnia affects approximately one-third of adults globally, imposing substantial health burdens with limited effective treatments. Transcranial al
- 19 February 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessTranscranial alternating current stimulation for chronic insomnia: a meta-analytic evaluation of sleep restoration and safety in adults
Chronic insomnia affects approximately one-third of adults globally, imposing substantial health burdens with limited effective treatments. Transcranial al
- Open Access
- 28 February 2025
- Published by The Korean Headache Society in Headache and Pain Research
- Vol. 26 (1) , 21-37
Does Atogepant Offer a Safe and Efficacious Option for Episodic Migraine Prophylaxis? A Systematic Review and Meta-analysis
Migraine, a chronic neurological disorder, imposes a significant burden on individuals and healthcare systems globally. This systematic review and meta-analysis evaluated the efficacy and safety of atogepant in preventing episodic migraine (EM) in adults. A systematic search was conducted in four major databases (PubMed, Scopus, Web of Science, and Cochrane CENTRAL) up to June 2024. The inclusion criteria targeted randomized controlled trials (RCTs) comparing atogepant to placebo or standard care in patients with EM. Statistical analyses were performed using Review Manager (RevMan) software. Four RCTs with 2,018 patients receiving atogepant and 761 patients receiving placebo or standard care were included. Atogepant significantly reduced monthly migraine days compared to placebo at 10 mg daily (mean difference [MD], –1.16 days; 95% confidence interval [95% CI], –1.60 to –0.73), 30 mg daily (MD, –1.15 days; 95% CI, –1.64 to –0.66), 60 mg daily (MD, –1.48 days; 95% CI: –2.36 to –0.61 days), 30 mg twice daily (MD, –1.30 days; 95% CI, –2.17 to –0.43), and 60 mg twice daily (MD, –1.20 days; 95% CI, –1.90 to –0.50). A ≥50% reduction in migraine days was frequently significantly achieved with atogepant across all dosages. Atogepant was generally well tolerated, though it was associated with higher incidence rates of constipation and nausea compared to placebo. Atogepant is an effective and well-tolerated option for preventing EM, offering patients a noninvasive oral alternative to injectable therapies. Further research is warranted to explore its long-term safety and efficacy in diverse patient populations and refine its role in this field.
- 28 February 2025
- Published by The Korean Headache Society in Headache and Pain Research
- Vol. 26 (1) , 21-37
Open AccessDoes Atogepant Offer a Safe and Efficacious Option for Episodic Migraine Prophylaxis? A Systematic Review and Meta-analysis
Migraine, a chronic neurological disorder, imposes a significant burden on individuals and healthcare systems globally. This systematic review and meta-analysis evaluated the efficacy and safety of atogepant in preventing episodic migraine (EM) in adults. A systematic search was conducted in four major databases (PubMed, Scopus, Web of Science, and Cochrane CENTRAL) up to June 2024. The inclusion criteria targeted randomized controlled trials (RCTs) comparing atogepant to placebo or standard care in patients with EM. Statistical analyses were performed using Review Manager (RevMan) software. Four RCTs with 2,018 patients receiving atogepant and 761 patients receiving placebo or standard care were included. Atogepant significantly reduced monthly migraine days compared to placebo at 10 mg daily (mean difference [MD], –1.16 days; 95% confidence interval [95% CI], –1.60 to –0.73), 30 mg daily (MD, –1.15 days; 95% CI, –1.64 to –0.66), 60 mg daily (MD, –1.48 days; 95% CI: –2.36 to –0.61 days), 30 mg twice daily (MD, –1.30 days; 95% CI, –2.17 to –0.43), and 60 mg twice daily (MD, –1.20 days; 95% CI, –1.90 to –0.50). A ≥50% reduction in migraine days was frequently significantly achieved with atogepant across all dosages. Atogepant was generally well tolerated, though it was associated with higher incidence rates of constipation and nausea compared to placebo. Atogepant is an effective and well-tolerated option for preventing EM, offering patients a noninvasive oral alternative to injectable therapies. Further research is warranted to explore its long-term safety and efficacy in diverse patient populations and refine its role in this field.
- 1 January 2009
- Published by ASME International
- p. 411-419
Development of Flashback Resistant Low-Emission Micro-Mixing Fuel Injector for 100% Hydrogen and Syngas Fuels
The present work extends previous efforts using “micro-mixing” fuel injectors operating on hydrogen fuel to elevated pressure and temperature and includes initial evaluation of a second injector concept. A micro-mixing fuel injector consists of multiple, small and closely spaced mixing cups, within which fuel and air mix rapidly at a small scale. The micro-mixing injection strategy offers inherent flexibility for the accommodation of staging, dilution, and fuel flexibility, and the manufacturing technology employed for building the cups affords great flexibility to address the conflicting demands of superior fuel-air mixing and flash-back avoidance. In the present work, both radial and axial flow micromixing concepts are investigated using experiments and computational fluid dynamics. The hydrogen/air reaction structure is captured using OH* chemiluminescence at 308 nm, recorded using a 16-bit thermoelectrically cooled ICCD with a UV sensitive phosphor. Instantaneous images are used to assess flashback tendencies at pressures up to 8 atm for reaction temperatures approaching 2000 K. Emissions are measured at the exit of the combustor liner using EPA certified methodologies. The results demonstrate that both concepts can produce low NOx emissions while remaining robust relative to flashback and lean blowout. The radial concepts offer superior emissions performance, while the axial concepts offer superior flashback tendencies. Based on the results obtained to date, the micro-mixing approach appears promising relative to achieving flashback free operation with low emissions at pressures up to 8 atm while maximizing scalability and fuel flexibility.
- 1 January 2009
- Published by ASME International
- p. 411-419
Development of Flashback Resistant Low-Emission Micro-Mixing Fuel Injector for 100% Hydrogen and Syngas Fuels
The present work extends previous efforts using “micro-mixing” fuel injectors operating on hydrogen fuel to elevated pressure and temperature and includes initial evaluation of a second injector concept. A micro-mixing fuel injector consists of multiple, small and closely spaced mixing cups, within which fuel and air mix rapidly at a small scale. The micro-mixing injection strategy offers inherent flexibility for the accommodation of staging, dilution, and fuel flexibility, and the manufacturing technology employed for building the cups affords great flexibility to address the conflicting demands of superior fuel-air mixing and flash-back avoidance. In the present work, both radial and axial flow micromixing concepts are investigated using experiments and computational fluid dynamics. The hydrogen/air reaction structure is captured using OH* chemiluminescence at 308 nm, recorded using a 16-bit thermoelectrically cooled ICCD with a UV sensitive phosphor. Instantaneous images are used to assess flashback tendencies at pressures up to 8 atm for reaction temperatures approaching 2000 K. Emissions are measured at the exit of the combustor liner using EPA certified methodologies. The results demonstrate that both concepts can produce low NOx emissions while remaining robust relative to flashback and lean blowout. The radial concepts offer superior emissions performance, while the axial concepts offer superior flashback tendencies. Based on the results obtained to date, the micro-mixing approach appears promising relative to achieving flashback free operation with low emissions at pressures up to 8 atm while maximizing scalability and fuel flexibility.